CN103214370B - 1, 6-O-dicaffeoyl sorbitol ester as well as derivative thereof and application - Google Patents
1, 6-O-dicaffeoyl sorbitol ester as well as derivative thereof and application Download PDFInfo
- Publication number
- CN103214370B CN103214370B CN201310121476.6A CN201310121476A CN103214370B CN 103214370 B CN103214370 B CN 103214370B CN 201310121476 A CN201310121476 A CN 201310121476A CN 103214370 B CN103214370 B CN 103214370B
- Authority
- CN
- China
- Prior art keywords
- compound
- derivative
- sorbitol ester
- dicaffeoyl
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of a compound, and in particular relates to 1, 6-O-dicaffeoyl sorbitol ester as well as a derivative thereof. The general formula of the 1, 6-O-dicaffeoyl sorbitol ester and the derivative is shown in the specification. The prepared 1, 6-O-dicaffeoyl sorbitol ester has a strong effect for inhibiting the proliferation and differentiation of preadipocyte 3T3-L1 and eliminating DPPH free radicals. The invention provides application of the prepared 1, 6-O-dicaffeoyl sorbitol ester and the derivative thereof to producing drugs for treating the obesity and diseases caused by the obesity such as hyperlipidemia, hypertension, diabetes mellitus, fatty liver, coronary heart disease, sleep apnea syndrome and the like as well as the medicines and healthcare products related to the diseases, application to medicines or healthcare use for delaying senescence, improving the immunity and preventing the cancers, and application to an antioxidant and the like.
Description
Technical field
The present invention relates to compound field, be specifically related to 1,6-O-bis-caffeoyl sorbitol ester and derivative thereof.
Background technology
Obesity is a kind of chronic disease, according to World Health Organization's statistics, is the most easily ignored by people, but a kind of disease that sickness rate sharply rises, obesity patient often merges hyperlipidemia.Obesity and many major diseases such as diabetes, cardiovascular and cerebrovascular diseases, cancer, sleep apnea syndrome etc. have substantial connection, and prevention and therapy obesity has become global facing challenges.
In each adult body, approximately containing 30,000,000,000 adipocytes, in each adipocyte, all contain triacylglycerol fat, be commonly called as Oil globule.Oil globule quantitative change is large, and adipocyte volume is amplification just, causes obesity.PECTORAL LIMB SKELETON 3T3-L1 can specifically differentiation-inducing become ripe adipocyte, be the important cell model of Study of functional composition to external lipocyte proliferation atomization.
Meeting oxygen intake in human body respiration process, but oxygen is in body metabolism process, an electronics can be lost and produce free radical, because free radical is in the state of extremely unstable, so body other material interior can be grabbed as protein, enzyme, the electronics (oxidising process) of DNA etc. and tending towards stability, these materials are destroyed, produce various disease, free radical makes people old and feeble gradually, produce the one of the main reasons of various disease, so the compound with free radical scavenging effect can reduce the damage of radical pair body, play antisenility function and resist the generation of various disease.
DPPH base (1,1-phenylbenzene-2-trinitrophenyl-hydrazine) be a kind of stable free radical, its ethanolic soln is purple, be strong absorption at wavelength 517nm, when there being free-radical scavengers to exist, the lone-pair electron of DPPH are paired, thus make it fade, it is quantitative relationship that fading extent and its electronics receive degree, thus can carry out quantitative analysis by colorimetry.DPPH method is widely used in scavenging free radicals and the resistance of oxidation of quantitative assay functional ingredient.
Sibiraea angustata (Sibiraea angustata (Rehd.) Hand.-Mazz) is Rosaceae Sibirae, for Tibetan's common drug among the people, its leaf and spray are used as medicine, have another name called willow tea, have clearing away the stomach-heat, aid digestion, regulate lipometabolic effect and its extract to have antioxygenation.
The present inventor extracts and solvent extraction Sibiraea angustata, obtain effective part extract, to effective part extract by purification on normal-phase silica gel and dextrane gel chromatography purifying repeatedly, obtain having the active compound suppressing PECTORAL LIMB SKELETON proliferation and differentiation and remove DPPH Free Radical, again through 1D NMR, 2D NMR, ESI-MS and HR-ESI-MS technology determines its chemical structure, this structure is the Phenylpropanoid Glycosides phenol polyhydric alcohol ester compound 1 of the novel structure that forefathers do not report, 6-O-bis-caffeoyl sorbitol ester, the present inventor has also prepared 1 of tool general formula I by the method for synthesis, 6-O-bis-caffeoyl sorbitol ester and derivative thereof.General formula (I) compound, containing phenolic hydroxyl group, alcoholic extract hydroxyl group in structural framework, or decomposable asymmetric choice net goes out phenolic hydroxyl group, carboxyl and/or amino, hydrogen needed for quenching activity free radical can be provided thus eliminate free radical, can it be made to lose the ability of catalysis lipid oxidation by chelated metal ions, thus hinder the generation of oxidizing reaction; Can be combined with cholesterol or cholic acid, form the difficult macromolecular substance absorbed and excreted by enteron aisle, reduce the absorption of fat; Have and suppress PECTORAL LIMB SKELETON proliferation and differentiation activity and Free-radical scavenging activity.Therefore the prevention and treatment of diseases such as hyperlipidemia, hypertension, diabetes, fatty liver, coronary heart disease, sleep apnea syndrome that can be used for obesity and caused by obesity, and for the medicine of delay senility, improve immunity of organisms, preventing cancer etc. or health caring use, can as the antioxidant of food etc.
Summary of the invention
The object of this invention is to provide and a kind of there is compound 1, the 6-O-bis-caffeoyl sorbitol ester and derivative thereof and pharmacologically acceptable salt that suppress PECTORAL LIMB SKELETON 3T3-L1 proliferation and differentiation.
Another object of the present invention is to provide 1,6-O-bis-caffeoyl sorbitol ester and derivative thereof and is used for prevention and therapy obesity and the medicine of the disease such as hyperlipidemia, hypertension, diabetes, fatty liver, coronary heart disease, sleep apnea syndrome caused by obesity and the medicine relevant with above-mentioned disease and healthcare products purposes.
Another object of the present invention is to provide 1,6-O-bis-caffeoyl sorbitol ester and derivative thereof for the medicine of delay senility, improve immunity of organisms, preventing cancer etc. or health caring use.
Another object of the present invention is to provide 1,6-O-bis-caffeoyl sorbitol ester and derivative thereof the purposes as antioxidants such as food.
1,6-O-bis-caffeoyl sorbitol ester and derivative thereof prepared by the present invention, its general formula is as follows:
Wherein, R
1monosubstituted or polysubstituted H, OH, C can be represented
1-5alkoxyl group, C
1-5alkyl, methylene-dioxy; R
2monosubstituted or polysubstituted H, OH, C can be represented
1-5alkoxyl group, C
1-5alkyl, methylene-dioxy; X can represent O, NH, S etc.; Y can represent O, NH, S etc.
Wherein, compound 1,6-O-bis-caffeoyl sorbitol ester: R
1be 3 ', 4 '-dihydroxyl, R
2be 3 ", 4 "-dihydroxyl, its chemical structural formula is as (1):
According to the present invention, the compound pharmacy acceptable salt of above-mentioned general formula (I) can be the additive salt formed with following amido or metal ion: NH
4 +, Na
+, K
+, Mg
2+, Li
+, Ca
2+, Sr
2+, Ca
2+, Zn
2+deng.
Formula (1) is mainly derived from Sibiraea angustata (Sibiraea angustata (Rehd.) Hand.-Mazz), it can be the arbitrary position of Sibiraea angustata, namely can be root, stem, leaf, flower, fruit, seed, also can be mixing position, preferably upper part.
According to the present invention, the extracting method of formula (1) compound comprises the following steps:
(1) Sibiraea angustata (Rehd.) Hand.-Mazz. and the spray of drying and crushing is got, by hot water (can use methyl alcohol (10-70%) aqueous solution, ethanol (10-70%) solution, acetone (10-70%) solution) refluxing extraction, concentrating under reduced pressure removes desolventizing and obtains 1.2kg semi-fluid shape medicinal extract;
(2) semi-fluid shape medicinal extract add water (1L) dispersion after, sherwood oil (3 × 1L), methylene dichloride (3 × 1L), ethyl acetate (3 × 1L) is used to extract successively, concentrated extract, obtains sherwood oil medicinal extract (150g) methylene dichloride medicinal extract (420g), ethyl acetate extract (210g);
(3) to ethyl acetate extract (100g) through silica gel column chromatography, adopt petroleum ether-ethyl acetate gradient elution, obtain A(35g), B(45g), C(8g) three part medicinal extract.To C medicinal extract again through silica gel column chromatography, adopt petroleum ether-ethyl acetate (3:1-0:1, volume ratio) wash-out, obtain compound (1) crude product (3.2g).Compound (1) crude product is through Sephadex LH-20 gel column chromatography (wash-out methyl alcohol (10%-70%) aqueous solution gradient elution) repeatedly, and obtain sterling compound (1) (350mg), its yield is 0.0035%.Compound (1), pale yellow powder, dissolves in methyl alcohol, ethanol and water, [α]
d 20-7.2 (c0.50, MeOH), molecular weight is 506, can use molecular formula C
24h
26o
12represent, called after 1,6-O-bis-caffeoyl sorbitol ester.
According to the present invention, the preparation of logical formula I compound is prepared by the reaction scheme below:
Wherein, in formula II and III compound, R
1monosubstituted or polysubstituted H, OH, C can be represented
1-5alkoxyl group, C
1-5alkyl, methylene-dioxy; R
2monosubstituted or polysubstituted H, OH, C can be represented
1-5alkoxyl group, C
1-5alkyl, methylene-dioxy; Z refers to halogen, specifically refers to chlorine, bromine, fluorine or iodine.
Wherein, in formula IV compound, X can represent O, NH, S etc.; Y can represent O, NH, S etc.
As follows for the concrete synthesis step of general formula compound (I): to utilize the hydroxyl of TBSCl to each compound of formula II, III and IV to protect in advance; then in organic solvent; under alkali presence or absence; reacting under stirring; obtain compound V; at room temperature utilize TBAF to go siliconizing to compound V, generate general formula compound (I).Wherein organic solvent is selected from pyridine, triethylamine, dimethyl formamide, methyl-sulphoxide, methylene dichloride, trichloromethane, benzene, toluene, nitrile, acetone etc., and alkali is selected from organic bases or mineral alkali, as imidazoles, pyridine, triethylamine, K
2cO
3, Na
2cO
3, NaHCO
3, KHCO
3deng.
Feature of the present invention is, the compound (1) of purifying from Sibiraea angustata and derivative (see general formula (I)) thereof have important biological activity, there is the effect suppressing PECTORAL LIMB SKELETON 3T3-L1 proliferation and differentiation and remove DPPH free radical, provide can be used for that obesity and obesity cause hyperlipidemia, hypertension, diabetes, fatty liver, coronary heart disease, the medicine of the diseases such as sleep apnea syndrome and the medicine relevant with above-mentioned disease and healthcare products purposes, provide for delaying senility, improve immunity of organisms, the medicine of preventing cancer etc. or health caring use, and for the purposes of the antioxidants such as food.
Accompanying drawing explanation
It is compound (1) shown in Fig. 1
1h NMR composes, (400MHz, CD
3oD) δ.
It is compound (1) shown in Fig. 2
13c NMR composes, (100MHz, CD
3oD) δ.
DEPT-135 spectrum (100MHz, the CD of compound (1) shown in Fig. 3
3oD) δ.
It is compound (1) shown in Fig. 4
1h-
1h COSY composes.
It is the hsqc spectrum of compound (1) shown in Fig. 5.
The HMBC spectrum of compound shown in Fig. 6 (1).
The ESI-MS spectrum of compound shown in Fig. 7 (1).
The early stage clonal expansion differentiation restraining effect of compound (1) to PECTORAL LIMB SKELETON 3T3-L1 shown in Fig. 8.
Fig. 9 shows compound (1) to PECTORAL LIMB SKELETON 3T3-L1LDH release rate.
Figure 10 shows oil red O staining method research compound (1) place and suppresses (490nm place absorbance) the differentiation of PECTORAL LIMB SKELETON 3T3-L1.
By embodiment below, the present invention is described in further detail, but these embodiments not meaning that any restriction of the present invention.
Embodiment
Embodiment 1
The preparation of compound (1)
Get Sibiraea angustata (Rehd.) Hand.-Mazz. and the spray 10kg of drying and crushing, by hot water (can use methyl alcohol (10-70%) aqueous solution, ethanol (10-70%) solution, acetone (10-70%) solution) refluxing extraction, concentrating under reduced pressure removes desolventizing and obtains 1.2kg semi-fluid shape medicinal extract.
Semi-fluid shape medicinal extract adds water after (1L) dispersion, sherwood oil (3 × 1L), methylene dichloride (3 × 1L), ethyl acetate (3 × 1L) is used to extract successively, concentrated extract, obtains sherwood oil medicinal extract (150g) methylene dichloride medicinal extract (420g), ethyl acetate extract (210g).
To ethyl acetate extract (100g) through silica gel column chromatography, adopt petroleum ether-ethyl acetate gradient elution, obtain A(35g), B(45g), C(8g) three part medicinal extract.To C medicinal extract again through silica gel column chromatography, adopt petroleum ether-ethyl acetate (3:1, volume ratio) wash-out, obtain compound (1) crude product (3.2g).Compound (1) crude product is through Sephadex LH-20 gel column chromatography (wash-out methyl alcohol (10%-70%) aqueous solution gradient elution) repeatedly, and obtain sterling compound (1) (350mg), its yield is 0.0035%.Compound (1), pale yellow powder, dissolves in methyl alcohol, ethanol and water, [α]
d 20-7.2 (c0.50, MeOH), molecular weight is 506, can use molecular formula C
24h
26o
12represent, and according to IUPAC nomenclature called after 1,6-O-bis-caffeoyl sorbitol ester (1,6-O-dicaffeoyl sorbitol).Compound (1) adopts the spectroscopic techniques (see accompanying drawing 1-7) such as 1D NMR, 2D NMR, ESI-MS and HR-ESI-MS to determine molecular structure, its
1h NMR and
13c NMR data are in table 1.
Table 1 compound (1)
1h NMR,
13c NMR data (CD
3oD δ ppm, J Hz)
The synthesis of embodiment 2 compound (1)
The synthesis of compound (1) adopts following reaction scheme to carry out:
Its concrete reactions steps is as follows:
(1) in above-mentioned reaction scheme, take sorbyl alcohol as initiator, by sorbyl alcohol (1.82g) and TBSCl(6.2 equivalent, 9.3g) and imidazoles, room temperature reaction 8 hours in DMF, obtains product 1-1.By coffic acid and TBSCl and imidazoles, in DMF, room temperature reaction 3 hours, obtains compd B.
(2) by product 1-1 in step (1) at 1%I
2room temperature reaction in-MeOH solution, obtains product 1-2(4.7g).Compd B and above-mentioned product 1-2 are carried out EDC condensation, obtains product 1-3.Product 1-3 is repeated this operation, obtains product 1-5.
(3) by product 1-5 in step (2) at ambient temperature, TBS group in product 1-5 can be sloughed with the tetrahydrofuran solution (adding several Glacial acetic acid) of TBAF, obtain compound (1) (1.52g), overall yield about 30%.Compound (1), pale yellow powder, ESI-MS:m/z507.2 [M+H]
+,
1h NMR δ 6.93 (2H, d, J=2.0Hz), 6.65 (2H, d, J=8.1Hz), 6.82 (2H, dd, J=8.2, 2.0Hz), 7.46 (2H, d, J=16.0Hz), 6.21 (1H, d, J=15.8Hz), 6.18 (1H, d, J=15.8Hz), 4.24 (1H, dd, J=11.5, 4.3Hz), 4.18 (1H, d, J=11.5Hz), 3.96 (1H, m), 3.86 (1H, dd, J=5.0, 1.8Hz), 3.63 (1H, dd, J=8.4, 1.7Hz), 3.89 (1H, m), 4.37 (1H, dd, J=11.6, 2.6Hz), 4.15 (1H, d, J=11.6Hz).
13C NMRδ169.1,169.0,149.1,149.0,147.1,147.0,146.3,126.1,126.0,121.2,121.1,114.3,114.2,113.3,114.1,71.4,69.1,68.5,68.1,64.8,64.7.
The synthesis of embodiment 3 compound 1,6-bis-caffeoyl sorbyl alcohol acid amides
The synthesis of compound 1,6-bis-caffeoyl sorbyl alcohol acid amides adopts following reaction scheme to carry out:
Its concrete reactions steps is as follows:
(1) with 1,6-bis-deoxidation-1,6-diamino sorbyl alcohol for initiator, by 1,6-bis-deoxidation-1,6-diamino sorbyl alcohol (1.82g) and TBSCl (9.3g, 6.2 equivalents) and imidazoles, room temperature reaction 8 hours in DMF, obtains product 2-1.By coffic acid and TBSCl and imidazoles, in DMF, room temperature reaction 3 hours, obtains compd B.
(2) product 2-1 in step (1) and compd B are carried out EDC condensation, obtain product 2-2.
(3) by product 2-2 in step (2) at ambient temperature; the TBS group in two coffee acyl sorbyl alcohol amide derivatives can be sloughed smoothly with the tetrahydrofuran solution (adding several Glacial acetic acid) of TBAF; obtain compound 1,6-bis-caffeoyl sorbyl alcohol acid amides (3.08g), overall yield about 66%.
Compound 1,6-bis-caffeoyl sorbyl alcohol acid amides: ESI-MS:m/z505.1 [M+H]
+;
1h NMR:
1h NMR δ 6.88 (2H, d, J=2.0Hz), 6.59 (2H, d, J=8.1Hz), 6.84 (2H, dd, J=8.2,2.0Hz), 7.43 (2H, d, J=16.0Hz), 6.22 (1H, d, J=15.8Hz), 6.16 (1H, d, J=15.8Hz), 4.12 (1H, dd, J=11.5,4.3Hz), 4.05 (1H, d, J=11.5Hz), 3.92 (1H, m), 3.81 (1H, m), 3.63 (1H, m), 3.89 (1H, m), 4.28 (1H, dd, J=11.6,2.6Hz), 4.08 (1H, d, J=11.6Hz).
13c NMR δ 167.1,167.0,148.1,145.0,146.1,146.0,145.3,126.1,126.0,121.8,121.7,114.2,113.3,113.3,113.2,71.3,71.0,69.0,68.1,65.4,65.0.
The growth-inhibiting of embodiment 4 couples of PECTORAL LIMB SKELETON 3T3-L1
PECTORAL LIMB SKELETON 3T3-L1 is by 5 × 10
4the density of individual/mL is inoculated into 6 well culture plates, at DMEM in high glucose substratum 37 DEG C, 5%CO containing 10% calf serum
2cultivate in incubator.Discard nutrient solution after 24h, wherein 3 holes, hole add the nutrient solution (150 ~ 1500 μ g/mL) that 100 μ L contain the compound (1) of different mass concentration, with the DMEM in high glucose not containing sample for blank, and incubation 72h.After removing nutrient solution, the DMEM10 substratum added containing 0.5mg/mL MTT incubates 4h, then adds 0.1g/mLSDS (containing the 0.1mol/L HCl) solutions overnight of 100 μ L, to dissolve MTT purple crystal product completely.Optical density value is measured 570nm place (taking 630nm as reference wavelength) by microplate reader.Experiment repetition 3 times.Carry out straight-line regression with the logarithm of drug level and cell survival rate and obtain IC
50(half-inhibition concentration, required drug level when namely cell survival rate is 50%).
As can be seen from Figure 8, compound (1) has a significant restrained action to 3T3-L1 PECTORAL LIMB SKELETON.Along with the rising (150 ~ 900 μ g/mL) of compound (1) concentration, its cytostatic ability strengthens, and dose-effect relationship is remarkable, and cell survival rate is down to 10% from about 100%.When extract quality concentration is between 900 ~ 1500 μ g/mL, cell survival rate is substantially constant.As calculated, compound (1) is (214.2 ± 20.2) μ g/mL to the growth inhibiting IC50 of 3T3-L1 PECTORAL LIMB SKELETON.Test-results shows that compound (1) has obvious growth-inhibiting effect to Swiss murine preadipocyte cell 3T3-L1, presents remarkable dosage effect.
Embodiment 5 serum lactic dehydrogenase (LDH, lactate dehydrogenase) burst size detects
Get 6 well culture plates, it is 5 × 10 that every hole adds 1mL3T3-L1 PECTORAL LIMB SKELETON concentration
4individual/mL.In 37 DEG C, cultivate in 5%CO2 incubator.Discard DMEM nutrient solution after 24 hours, add the nutrient solution of 1mL compound (1) in 3 holes respectively, adding respectively in 3 holes is not blank containing the DMEM nutrient solution of sample, respectively at 24,48,72h collects supernatant liquor, the centrifugal 10min of 500 × g.Get 50 μ L centrifugal after supernatant liquor and 2mL Tris-EDTA-NADH solution (containing 50mmol/L Tris damping fluid, pH7.4,37 DEG C; 5mmol/L EDTA; 150 μm of ol/L NADH) mixing, incubation 12min, then add 200 μ L preheatings (37 DEG C) 13.5mmol/L sodium pyruvate solution excessively, mix, in 37 DEG C, 340nm wavelength microplate reader mensuration Δ OD value.Replicate(determination) 3 times.Result represents with LDH release rate (sample LDH burst size and the ratio contrasting LDH burst size).
Experimental result (Fig. 9) shows, and after compound (1) process, the LDH release rate of 3T3-L1 cell does not increase (24 ~ 48h), has minimizing after 72 hours on the contrary.Test-results shows that compound (1) does not realize by changing permeability of cell membrane the growth-inhibiting effect of 3T3-L1 PECTORAL LIMB SKELETON.
The differentiation of embodiment 6 compound (1) PECTORAL LIMB SKELETON 3T3-L1 suppresses
3T3-L1 cell is inoculated into 24 well culture plates, if control group and compound (1) group.DMEM nutrient solution not containing sample is blank, and the concentration of compound (1) is 12.5,25.0,50 μm of ol/L.Cultivate in the DMEM in high glucose substratum containing lO% calf serum 37 DEG C, 5%CO2 incubator, start to add division culture medium when cell reaches 70% fusion, wherein containing Regular Insulin O.25 μm ol/L, thyroxine 0.2nmol/L, dexamethasone O.25 μm ol/L, IBMX be O.5nmol/L.Within every 48 hours, change liquid 1 time, to differentiation-inducing the 12nd day, by cell oil red O stain, extract oil red O dye liquor, survey and absorbancy (A) value at spectrophotometer 490nm wavelength place.
The display of red O stain test result (Figure 10), the 12nd day of differentiation, compare with control group, the triglyceride level (TG) produced in each group of adipocyte 3T3-L1 that compound (1) processes is all lower than control group.Illustrate that compound (1) obviously can suppress the differentiation of PECTORAL LIMB SKELETON, and its restraining effect presents remarkable dosage effect.
Embodiment 7 compound (1) is to DPPH free radical scavenging effect
By compound (1) accurate weighing, be configured to 50% ethanolic soln that concentration is 10.0,20.0,30.0,40.0,50.0,60.0 μMs successively, get 50% ethanolic soln of the compound (1) of each concentration of 1mL respectively, add 2mL0.1mM DPPH50% ethanolic soln, abundant mixing, under room temperature, lucifuge reaction 30min, surveys it at 525nm place light absorption value.Sample is replaced to do blank with 1mL50% ethanol.Using Vc as positive control drug.With following formula computerized compound to DPPH radical scavenging activity: (%)=(A0-A1)/A0 × 100, wherein A0 is blank absorbency, and A1 is sample light absorption value.Calculate Vc to DPPH free radical half elimination ratio IC
50be 28 μMs, compound (1) is to DPPH free radical half elimination ratio IC
50it is 15 μMs.DPPH free radical scavenging test-results represents, compared with positive control, compound (1) has the effect of stronger scavenging free radicals.Can be used for anti-ageing, to improve immunity of organisms and preventing cancer, natural food antioxidant etc. the purposes such as medicine, health care, foodstuffs industry.
Compound of the present invention (I), can be combined with pharmaceutically conventional auxiliary material or carrier, prepare and there is functions of lowering blood-fat and reducing weight or delay senility, improve immunizing power, preventing cancer, oxidation resistant medicine and pharmaceutical composition or healthcare products, above-mentioned various kinds of drug composition or healthcare products can adopt the drug forms such as tablet, capsule, injection, aerosol, suppository, film, pill, externally-applied liniment, ointment, comprise the preparation of pharmaceutics general knowledge routine and the various slowly-releasings, controlled release form or the nanometer formulation that obtain that employing now generally acknowledged.
Claims (8)
1. the compound of structure shown in a tool formula (I):
Wherein, R
1for monosubstituted or polysubstituted H, OH, C
1-5alkoxyl group, C
1-5alkyl or methylene-dioxy; R
2for monosubstituted or polysubstituted H, OH, C
1-5alkoxyl group, C
1-5alkyl or methylene-dioxy; X is O, NH or S; Y is O, NH or S,
Wherein R
1, R
2be asynchronously H, and be O when X, Y are different.
2. compound according to claim 1, is characterized in that, described compound is 1,6-O-bis-caffeoyl sorbitol ester, wherein, and R
1be 3 ', 4 '-dihydroxyl, R
2be 3 ", 4 "-dihydroxyl, X is O, Y is O.
3. the derivative of compound described in claim 1.
4. the pharmacy acceptable salt of compound described in claim 1.
5. pharmacy acceptable salt according to claim 4, is characterized in that, described salt is the additive salt that the compound of general formula (I) and following amido or metal ion are formed
Described amido is NH
4 +
Described metal ion is Na
+, K
+, Mg
2+, Li
+, Ca
2+, Sr
2+, Ca
2+or Zn
2+.
6. compound according to claim 1 and derivative thereof and the pharmacy acceptable salt application in the medicine for the preparation of prevention and therapy obesity and the hyperlipidemia caused by obesity, hypertension, diabetes, fatty liver, coronary heart disease, sleep apnea syndrome.
7. compound according to claim 1 and derivative thereof and pharmacy acceptable salt are for the preparation of the application in the medicine of the immunity of organisms that delays senility, improves, preventing cancer or healthcare products.
8. compound according to claim 1 and derivative thereof are for the preparation of the purposes of antioxidant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310121476.6A CN103214370B (en) | 2013-04-09 | 2013-04-09 | 1, 6-O-dicaffeoyl sorbitol ester as well as derivative thereof and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310121476.6A CN103214370B (en) | 2013-04-09 | 2013-04-09 | 1, 6-O-dicaffeoyl sorbitol ester as well as derivative thereof and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103214370A CN103214370A (en) | 2013-07-24 |
| CN103214370B true CN103214370B (en) | 2015-04-22 |
Family
ID=48812591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310121476.6A Active CN103214370B (en) | 2013-04-09 | 2013-04-09 | 1, 6-O-dicaffeoyl sorbitol ester as well as derivative thereof and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103214370B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106554282B (en) * | 2016-11-17 | 2019-07-12 | 中国科学院西北高原生物研究所 | Phenolic compound and application thereof of the one kind containing sorbitol ester group |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241269A (en) * | 2001-02-16 | 2002-08-28 | Kaken Pharmaceut Co Ltd | Fat cell differentiation inhibitor containing terrain |
| CN101104628A (en) * | 2006-07-13 | 2008-01-16 | 桂林莱茵生物科技股份有限公司 | 6-oxy-caffeoyl-arbutin, rock tea extract containing the same and preparation method |
| CN101732441B (en) * | 2010-01-22 | 2012-03-07 | 北京师范大学 | Extract of effective part of sibiraea augustata(rehd.) hand-mazz for preventing adiposity and lowering hyperlipoidemia, preparation method and application thereof |
| CN102000051B (en) * | 2010-11-24 | 2011-12-21 | 山东省科学院生物研究所 | Application of 5-caffeoylquinic acid in preparing anti-tumor drugs |
| CN102188515B (en) * | 2011-04-24 | 2012-12-12 | 兰州大学 | Purpose of the plant Sibiraea angustata |
-
2013
- 2013-04-09 CN CN201310121476.6A patent/CN103214370B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103214370A (en) | 2013-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102432663B (en) | Celastrol derivative and preparation method thereof and application of celastrol derivative to preparation of antitumor medicine | |
| CN104586945A (en) | Hop total flavonoid extract as well as preparation method and application thereof in preparing medicines for preventing and treating liver injury and cancers | |
| CN105920064A (en) | Natural active ingredient extracted and separated from leaves and stems of panax quinuefolium L and application of natural active ingredient | |
| CN106008502A (en) | Alkaloid compounds with novel skeletons in purslane and extraction and separation method thereof | |
| CN101642450B (en) | New application of dicaffeoylquinic acid | |
| CN110437247B (en) | Mixed source terpenoid with liver protection function and application thereof | |
| CN106977467A (en) | A kind of compound and preparation method thereof and purposes | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN103110655A (en) | Application of purslane alkaloid monomeric compound in preparation of anti-tumor medicament | |
| CN102786562B (en) | Pyrrolizidine alkaloids and purpose thereof | |
| CN103214370B (en) | 1, 6-O-dicaffeoyl sorbitol ester as well as derivative thereof and application | |
| CN106966997A (en) | A kind of compound and preparation method thereof and purposes | |
| CN101392010B (en) | Shikonin carbohydrate derivatives and synthetic method and use thereof | |
| CN103880826A (en) | Isobenzofuranone compounds as well as preparation method and application thereof | |
| CN103610682B (en) | The preparation method of 3 Alpha-hydroxy-30-olive-12,20 (29)-diene-28-acid and preparing the application in antitumor drug | |
| CN102898322B (en) | Compound and preparation method and application thereof | |
| CN105481876A (en) | Diterpene compound for treating ovarian cancer | |
| CN103044377B (en) | Compounds and composition with effects of inhibiting xanthine oxidase and reducing uric acid | |
| CN104370931A (en) | New flavone compound as well as preparation method and application thereof | |
| CN105663102B (en) | A kind of application of phenol amides compound in prevention and treatment cerebral injury | |
| KR100998573B1 (en) | Compositions of health functional foods for prevention of cancer containing Aster koraiensis extracts, fractions, the isolated Gymnasterkoreaynes derivatives therefrom or the pharmaceutically acceptable salts as an active ingredient | |
| CN103830214A (en) | Application of purslane alkaloid monomeric compound in preparation of antitumor drugs | |
| CN110305094A (en) | Two kinds of flavone compounds and its extraction separation method and purposes in purslane | |
| CN105566344B (en) | A kind of loop coil chromone and its preparation and application | |
| CN103694302B (en) | 2 α, the preparation method of 3 beta-dihydroxyl-30-olea-12,20 (29)-diene-28-acid and preparing the application in antitumor drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |